Resshidi Electric Wheelchair Receives FDA 510(k) Clearance, Accelerating Entry into the U.S. Rehabilitation Equipment Market

The U.S. Food and Drug Administration (FDA) has officially issued a 510(k) premarket notification clearance (K261396) for the Resshidi electric wheelchair, finding it substantially equivalent to legally marketed predicate devices. The clearance came 20 days ahead of the typical review schedule, marking a critical milestone in Resshidi’s expansion into the world’s largest rehabilitation device market.

Resshidi (Ningbo Resshidi Medical Devices Co., Ltd.), a Chinese manufacturer of electric wheelchairs, today announced that its independently developed electric wheelchair has officially received FDA 510(k) market clearance (K-number: K261396). The clearance was granted under Section 510(k) of the Federal Food, Drug, and Cosmetic Act, with the FDA determining that the device is substantially equivalent to other legally marketed devices of the same type, thereby permitting its legal sale in the U.S. market.

The cleared Resshidi electric wheelchair is classified as a Class II medical device, regulated under 21 CFR 890.3860 with product code ITI. It is indicated for use in providing mobility assistance to individuals with limited ambulation, both in clinical and home settings.

Compliance Management Capabilities Recognized by FDA

Resshidi demonstrated systematic compliance management throughout the review process. In its clearance letter, the FDA explicitly noted that the device is subject to the Quality Management System Regulation (QMSR, 21 CFR Part 820), which incorporates, among others, ISO 13485 requirements for design controls (Clause 7.3), nonconforming product (Clause 8.3), corrective action (Clause 8.5.2), and preventive action (Clause 8.5.3). Resshidi’s quality management documentation fully covers these requirements, laying a solid institutional foundation for potential future FDA factory inspections and ongoing regulatory compliance.

Additionally, the FDA reminded that all cleared devices must comply with the Unique Device Identification (UDI) System rule, requiring a UDI on labels and packaging, and submission of specified information to the Global Unique Device Identification Database (GUDID). Resshidi has already implemented UDI processes prior to market launch.

Providing Stronger Compliance Assurance for Overseas B2B Clients

For overseas distributors, pharmacy chains, and medical device procurement organizations, a supplier’s FDA market access status directly impacts customs clearance efficiency, eligibility for hospital procurement, and end-user confidence. Resshidi’s successful 510(k) clearance means its products have received endorsement from an internationally recognized regulatory authority in terms of safety, effectiveness, and quality management.

A Resshidi sales representative commented: “FDA clearance is not just a ‘passport’ to the U.S. market; it is a long‑term commitment to our B2B partners. We have a compliant R&D system, traceable production records, and internationally recognized quality language. This effectively reduces the compliance risks that overseas clients may face in their supply chains.”

Resshidi (Ningbo Resshidi Medical Devices Co., Ltd.) is a manufacturer integrating R&D, production, and sales of electric wheelchairs, dedicated to providing safe, reliable, and cost‑effective mobility solutions for people with limited mobility worldwide. The company strictly adheres to the ISO 13485 quality management system and exports its products to Europe, North America, Southeast Asia, the Middle East, and other regions. The FDA 510(k) clearance represents a significant milestone in Resshidi’s globalization strategy and reinforces its foundation for further expansion into the high‑end North American and global markets.